Drugs / Ga-68 P16-093
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03444844 | May 2018 → Oct 2020 overdue | prostate cancer | Five Eleven Pharma, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ga-68 P16-093 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03444844 ↗ |